Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,787 matching trials from the live ClinicalTrials.gov search.
Conditions
Malignant Solid Tumor
Interventions
Necitumumab, Gemcitabine, Cisplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Scottsdale, Arizona • Detroit, Michigan • Las Vegas, Nevada + 1 more
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
axitinib, chemotherapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Atlanta, Georgia • Decatur, Georgia + 8 more
Conditions
Malignant Mesothelioma
Interventions
liposomal NDDP, therapeutic thoracoscopy
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
mitomycin-c, cisplatin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Onalespib, Pharmacological Study
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Gainesville, Florida • Chapel Hill, North Carolina • Hendersonville, North Carolina + 2 more
Active, not recruiting Phase 2 Interventional Results available

Study of AZD2811 + Durvalumab in ES-SCLC

NCT04745689
Conditions
Small-Cell Lung Cancer
Interventions
Durvalumab, AZD2811, Carboplatin, Cisplatin, Etoposide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
Melanoma
Interventions
Palonosetron
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hearing Loss, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Nongerminomatous Germ Cell Tumor, Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor, Metastatic Testicular Seminoma, Stage II Testicular Cancer AJCC v8, Stage III Testicular Cancer AJCC v8
Interventions
Audiometric Test, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Sodium Thiosulfate Anhydrous
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Duarte, California
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Breast Cancer, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Triple Negative Breast Cancer
Interventions
Pembrolizumab, Cisplatin
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC), Ovarian Cancer, Solid Tumors
Interventions
INCB001158, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, Cisplatin, Paclitaxel
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 3 more
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2013
U.S. locations
15
States / cities
Urbana, Illinois • Indianapolis, Indiana • Cedar Rapids, Iowa + 10 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Atezolizumab, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine, Pemetrexed
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
45
States / cities
Fayetteville, Arkansas • Encinitas, California • Fountain Valley, California + 38 more
Conditions
Cancer of the Cervix
Interventions
Cetuximab
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
St Louis, Missouri • Charlottesville, Virginia
Conditions
Lung Cancer
Interventions
AMG 510, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Non-small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Lorlatinib, Cisplatin or Carboplatin, Pemetrexed
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Denver, Colorado • Asheville, North Carolina • Nashville, Tennessee + 2 more
Conditions
Lymphoma
Interventions
rituximab, cisplatin, cytarabine, dexamethasone, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
16 Years to 65 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Hackensack, New Jersey + 2 more
Conditions
Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma
Interventions
Atezolizumab, Gemcitabine, Cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Conditions
Head and Neck Cancer
Interventions
ZD6474 (vandetanib), Cisplatin, Radiation
Drug · Radiation
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Denver, Colorado • Chicago, Illinois • Dallas, Texas + 1 more
Conditions
Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity, Metastatic Squamous Cell Carcinoma of the Oropharynx, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Carboplatin, Cisplatin, Docetaxel, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
5
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Conditions
Biliary Tract Cancer
Interventions
Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Mobile, Alabama • Orange, California • Washington D.C., District of Columbia + 1 more
Conditions
Sarcoma
Interventions
cisplatin, ifosfamide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
21 Years to 120 Years · Female only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Gatos, California + 56 more
Conditions
Nasopharyngeal Cancer Recurrent
Interventions
Toripalimab, Cisplatin, Gemcitabine, Carboplatin
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Irvine, California • San Francisco, California + 9 more